Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.

Biotechnology

Foghorn Therapeutics

Adrian Gottschalk

Andrew Germain

Dan Dinu

Saurabh Sewak

Karin Hellsvik

Gromek Smolen

Danette L. Daniels

Steven Bellon

Michael Lacascia

Samuel Agresta

Murphy Hentemann

Carlos Costa

Chong-Hui Gu

Marina Nelen

Kevin Wilson

Fanny Cavalié

Ben Strain

The executive team at Foghorn Therapeutics has a history of experience in the financial and healthcare industries. The team members have worked at Pieris Pharmaceuticals, Lombard Odier Asset Management, Citi Principal Strategies, Trivium Capital Management, Biogen, McKinsey & Company, Lagardère, and Morgan Stanley. They have also been educated at Western University in Statistics.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at Foghorn Therapeutics

Leadership Team

Board of Directors